Scribd Logo
Upload

Welcome to Scribd!

  • Protaffin Technology Profile

    Uploaded by

    medgadget
    63 views1 page
    ProtAffin Biotechnologie AG has developed the novel CellJammer(r) discovery technology for developing anti-inflammatory and other products. We achieve an increase in GAG-binding affinity, without changing the specificity of GAG binding. Our aim is to develop novel antiinflammatory biologicals by targeting endothelial surface glycan structures for the first time.

    Original Description:

    Original Title

    080114 protaffin technology profile

    Copyright

    © Attribution Non-Commercial (BY-NC)

    Available Formats

    PDF, TXT or read online from Scribd

    Did you find this document useful?

    Is this content inappropriate?

    Report this Document
    ProtAffin Biotechnologie AG has developed the novel CellJammer(r) discovery technology for developing anti-inflammatory and other products. We achieve an increase in GAG-binding affinity, without changing the specificity of GAG binding. Our aim is to develop novel antiinflammatory biologicals by targeting endothelial surface glycan structures for the first time.

    Copyright:

    Attribution Non-Commercial (BY-NC)
    Download as PDF, TXT or read online from Scribd
    Flag for inappropriate content
    63 views1 page

    Protaffin Technology Profile

    Uploaded by

    medgadget
    ProtAffin Biotechnologie AG has developed the novel CellJammer(r) discovery technology for developing anti-inflammatory and other products. We achieve an increase in GAG-binding affinity, without changing the specificity of GAG binding. Our aim is to develop novel antiinflammatory biologicals by targeting endothelial surface glycan structures for the first time.

    Copyright:

    Attribution Non-Commercial (BY-NC)
    Download as PDF, TXT or read online from Scribd
    Flag for inappropriate content
    of 1

    CellJammer® discovery technology

    Overview Process
    ● Our Aim:
    ProtAffin Biotechnologie AG has ProtAffin uses the CellJammer®
    To develop novel anti-
    developed the novel CellJammer® discovery technology to create protein-
    inflammatory biologicals
    discovery technology for developing based GAG antagonists. We use
    by targeting endothelial
    anti-inflammatory and other products. structural bioinformatics for rational
    surface glycan structures
    We will work with Pharma/Biotech design of mutants, followed by
    for the first time.
    companies to apply our technology to proprietary assays to select optimal
    their targets of interest. therapeutics. We achieve an increase
    in GAG-binding affinity, without
    ● Relevant Targets
    Technology changing the specificity of GAG
    Relevant targets share binding. Secondly, we “inactivate“ the
    ProtAffin‘s co-Founder, Prof. Andreas target protein, e.g. by knocking-out the
    property of binding to
    Kungl is a leader in the field of GPCR activity of chemokines.
    glycans (GAGs). Initial
    protein-glycan interactions. Over the Following in vitro and cell-based
    focus is on chemokines
    last 10 years, it has been shown that characterisation, we work with
    but with wider applications.
    protein-glycan (i.e. Protein-GAG) partners to characterise the
    interactions drive many acute and pharmacology of the proteins in ex
    chronic inflammatory processes. vivo and in vivo disease models.
    ● Process
    ProtAffin has developed the
    Design and development CellJammer® discovery technology to Discovery
    In vitro
    studies
    In vivo
    models
    Pre-clinical
    development Phase I
    Disease
    indication

    of protein-based GAG create proteins with improved binding IL-8


    CellJammer™
    PA04-001
    I/R injury in transplant
    RA, others

    antagonists, taking 6 to disease-related GAGs, thereby Chemokine 2


    CellJammer™
    months from start to in
    Various

    acting as potent, targeted anti- PA05-008

    vivo characterisation. inflammatory products (ref.1). Chemokine 3


    CellJammer™
    PA05-017
    Various

    Target 4
    CellJammer™ Various
    PA06-001

    ● Advantages Partners

    Target Characterisation:
    Undisclosed Various indications

    Faster development of
    specific therapeutics than
    with glycan-based drugs, Advantages
    easier manufacturing and A number of companies have
    specificity more easily developed monoclonal antibodies to
    achieved GAG-binding proteins. This
    complication in target biology provides
    Model of an IL-8 monomer bound to a the chance to create superior
    ● Business Model GAG oligosaccharide therapeutics to mAbs when dealing
    ProtAffin works with Chemokines rely on protein-GAG with this significant class of complex
    partners to co-develop interactions for efficiently driving proteins. ProtAffin offers a new, fast
    therapeutics with usual cellular inflammation in diseases such track way to target protein-glycan
    milestone payments and as ischemia/reperfusion injury and interactions, avoiding the need for
    royalty entitlements rheumatoid arthritis. ProtAffin is complex carbohydrate chemistry and
    initially applying its discovery expensive manufacturing scale-up.
    technology to chemokines for the
    ● Collaborations development of anti-inflammatory References
    products (ref. 2). 1) Gesselbauer & Kungl, Curr. Op. Mol.
    We are currently Therap. 8, 521 (2006)
    collaborating with leading 2) Potzinger et al., Biochem. Soc.
    universities and are Transact. 34, 435 (2006)
    seeking Pharma/Biotech
    collaborations Contact: ProtAffin Biotechnologie AG
    Impulszentrum Graz-West, Reininghausstrasse 13a
    A-8020 Graz, Austria
    Web: www.protaffin.com
    Tel: +43 316 382 541
    January 2008 E-mail: office@protaffin.com

    You might also like